NASDAQ:UTHR - United Therapeutics Stock Price, Forecast & News

United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR."

United Therapeutics Co. (NASDAQ:UTHR) released its quarterly earnings data on Wednesday, October, 30th. The biotechnology company reported $3.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.34 by $0.82. The biotechnology company had revenue of $401.50 million for the quarter, compared to analysts' expectations of $342.28 million. United Therapeutics had a negative net margin of 6.04% and a negative return on equity of 3.54%. The company's revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.98 earnings per share. View United Therapeutics' Earnings History.

United Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for United Therapeutics.

10 brokerages have issued 1-year target prices for United Therapeutics' stock. Their forecasts range from $80.00 to $237.00. On average, they expect United Therapeutics' share price to reach $117.30 in the next twelve months. This suggests a possible upside of 26.0% from the stock's current price. View Analyst Price Targets for United Therapeutics.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 2 sell ratings, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for United Therapeutics.

News articles about UTHR stock have trended somewhat negative recently, InfoTrie reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. United Therapeutics earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for United Therapeutics.

Some companies that are related to United Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Celgene (CELG), Gilead Sciences (GILD), General Electric (GE), Biogen (BIIB), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), CytoDyn (CYDY), Nektar Therapeutics (NKTR), Allergan (AGN) and Johnson & Johnson (JNJ).

United Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Greylin Investment Mangement Inc. (0.36%), DNB Asset Management AS (0.27%), Nisa Investment Advisors LLC (0.05%), State of Alaska Department of Revenue (0.02%), Alpha Windward LLC (0.01%) and Alpine Global Management LLC (0.01%). Company insiders that own United Therapeutics stock include Christopher Causey, Christopher Patusky, Judy D Olian, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics.

UTHR stock was sold by a variety of institutional investors in the last quarter, including Greylin Investment Mangement Inc., Nisa Investment Advisors LLC, Wedbush Securities Inc. and State of Alaska Department of Revenue. Company insiders that have sold United Therapeutics company stock in the last year include Christopher Patusky, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Insider Buying and Selling for United Therapeutics.

UTHR stock was bought by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Alpine Global Management LLC and Alpha Windward LLC. View Insider Buying and Selling for United Therapeutics.

Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of UTHR stock can currently be purchased for approximately $93.13.

United Therapeutics has a market capitalization of $4.09 billion and generates $1.63 billion in revenue each year. The biotechnology company earns $589.20 million in net income (profit) each year or $13.39 on an earnings per share basis. United Therapeutics employs 860 workers across the globe.View Additional Information About United Therapeutics.

The official website for United Therapeutics is http://www.unither.com/.

United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The biotechnology company can be reached via phone at 301-608-9292 or via email at [email protected]